{"protocolSection":{"identificationModule":{"nctId":"NCT00807248","orgStudyIdInfo":{"id":"12213A"},"secondaryIdInfos":[{"id":"2008-000506-36","type":"REGISTRY","domain":"EudraCT"},{"id":"2008","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2008"}],"organization":{"fullName":"H. Lundbeck A/S","class":"INDUSTRY"},"briefTitle":"Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder","officialTitle":"Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study of Escitalopram in Combination With Two Fixed Doses of Gaboxadol Compared to Escitalopram in Major Depressive Disorder"},"statusModule":{"statusVerifiedDate":"2012-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-11"},"primaryCompletionDateStruct":{"date":"2009-12","type":"ACTUAL"},"completionDateStruct":{"date":"2010-02","type":"ACTUAL"},"studyFirstSubmitDate":"2008-12-10","studyFirstSubmitQcDate":"2008-12-10","studyFirstPostDateStruct":{"date":"2008-12-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-06-15","resultsFirstSubmitQcDate":"2011-07-15","resultsFirstPostDateStruct":{"date":"2011-08-11","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-12-13","lastUpdatePostDateStruct":{"date":"2012-12-17","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"H. Lundbeck A/S","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"To compare the efficacy of escitalopram fixed dose 20 mg/day in combination with fixed doses of gaboxadol (5 and 10 mg/day) versus escitalopram fixed dose 20 mg/day after 8 weeks of treatment in patients with Major Depressive Disorder","detailedDescription":"Subjects participating in this study will be respectively randomised (1:2:2:2) to receive either:\n\n* placebo or\n* escitalopram 20 mg/day or\n* escitalopram 20 mg/day in combination with gaboxadol 5 mg/day or\n* escitalopram 20 mg/day in combination with gaboxadol 10 mg/day"},"conditionsModule":{"conditions":["Major Depressive Disorder"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":490,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Escitalopram placebo and gaboxadol placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Escitalopram placebo","Drug: Gaboxadol placebo"]},{"label":"Escitalopram 20 mg and gaboxadol placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Gaboxadol placebo","Drug: Escitalopram 20 mg"]},{"label":"Escitalopram 20 mg and gaboxadol 5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Escitalopram 20 mg","Drug: Gaboxadol 5 mg"]},{"label":"Escitalopram 20 mg and gaboxadol 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Escitalopram 20 mg","Drug: Gaboxadol 10 mg"]}],"interventions":[{"type":"DRUG","name":"Escitalopram placebo","description":"Once daily before bedtime for 8 weeks","armGroupLabels":["Escitalopram placebo and gaboxadol placebo"]},{"type":"DRUG","name":"Gaboxadol placebo","description":"Once daily before bedtime for 8 weeks","armGroupLabels":["Escitalopram 20 mg and gaboxadol placebo","Escitalopram placebo and gaboxadol placebo"]},{"type":"DRUG","name":"Escitalopram 20 mg","description":"Once daily before bedtime for 8 weeks","armGroupLabels":["Escitalopram 20 mg and gaboxadol 10 mg","Escitalopram 20 mg and gaboxadol 5 mg","Escitalopram 20 mg and gaboxadol placebo"],"otherNames":["Escitalopram = Cipralex/Lexapro/Seroplex/Sipralexa"]},{"type":"DRUG","name":"Gaboxadol 5 mg","description":"Once daily before bedtime for 8 weeks","armGroupLabels":["Escitalopram 20 mg and gaboxadol 5 mg"]},{"type":"DRUG","name":"Gaboxadol 10 mg","description":"Once daily before bedtime for 8 weeks","armGroupLabels":["Escitalopram 20 mg and gaboxadol 10 mg"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Montgomery and Åsberg Depression Rating Scale (MADRS)","description":"The MADRS is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at 2-point intervals. The total score of the 10 items ranges from 0 to 60.","timeFrame":"Baseline to 8 weeks"}],"secondaryOutcomes":[{"measure":"MADRS","description":"The MADRS is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at 2-point intervals. The total score of the 10 items ranges from 0 to 60.","timeFrame":"From baseline to Week 8"},{"measure":"Hospital Anxiety and Depression Scale (HADS)","description":"The HADS is a patient-rated scale designed to screen for anxiety and depressive states in medical patients. It consists of two sub-scales: the D-scale measures depression and the A-scale measures anxiety. Each sub-scale contains 7 items, and each item is rated from 0 (absent) to 3 (maximum severity). The score of each sub-scale ranges from 0 to 21, and are analysed separately. The total HADS score ranges from 0 to 42.","timeFrame":"Mean change from baseline to Week 8"},{"measure":"Insomnia Severity Index (ISI)","description":"The ISI is both a brief screening measure of insomnia and an outcomes measure for use in treatment research. It is a brief self-report instrument measuring the patient's perception of his or her insomnia, and it comprises 7 items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28. 0 = no symptoms and 28 = severe symptoms.","timeFrame":"Mean change from baseline to Week 8"},{"measure":"Sheehan Disability Scale (SDS): Family Subscale","description":"The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment.","timeFrame":"Mean change from baseline to Week 8"},{"measure":"SDS: Work Subscale","description":"The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment.","timeFrame":"Mean change from baseline to Week 8"},{"measure":"SDS: Social Subscale","description":"The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment.","timeFrame":"Mean change from baseline to Week 8"},{"measure":"Clinical Global Impression - Severity of Illness (CGI-S)","description":"The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).","timeFrame":"Mean change from baseline to Week 8"},{"measure":"Clinical Global Impression - Global Improvement (CGI-I)","description":"The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).","timeFrame":"at Week 8"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nClinical Diagnosis of MDD according to DSM-IV-TR criteria:\n\n* With reported duration of the current major depressive episode of at least 3 months\n* With MADRS total score of at least 30\n\nExclusion Criteria:\n\nThe patient has 1 or more of the following:\n\n* Any current psychiatric disorder other than MDD as defined in the DSM-IV-TR\n* Current or past history of: manic or hypomanic episode, schizophrenia, or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR\n* Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR\n* Presence or history of a clinically significant neurological disorder (including epilepsy)\n* Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc)\n* Any Axis II disorder that might compromise the study\n* Previous use of hallucinogenic drug\n\nThe patient has a significant risk of suicide according to the investigator's opinion, or has a score \\>=5 on item 10 (suicidal thoughts) of the MADRS, or has made a suicide attempt in the previous 12 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Email contact via H. Lundbeck A/S","affiliation":"LundbeckClinicalTrials@lundbeck.com","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"AT001","city":"Vienna","zip":"1090","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"RU019","city":"Barnaul","zip":"656022","country":"Russia","geoPoint":{"lat":53.36199,"lon":83.72786}},{"facility":"RU029","city":"Izhevsk","zip":"426054","country":"Russia","geoPoint":{"lat":56.85225,"lon":53.19862}},{"facility":"RU020","city":"Kemerovo","zip":"650036","country":"Russia","geoPoint":{"lat":55.35417,"lon":86.10435}},{"facility":"RU012","city":"Krasnodar","zip":"350007","country":"Russia","geoPoint":{"lat":45.04534,"lon":38.98178}},{"facility":"RU010","city":"Krasnodar","zip":"350087","country":"Russia","geoPoint":{"lat":45.04534,"lon":38.98178}},{"facility":"RU022","city":"Kursk","zip":"30500","country":"Russia","geoPoint":{"lat":51.72689,"lon":36.18457}},{"facility":"RU015","city":"Moscow","zip":"107076","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"RU026","city":"Moscow","zip":"115522","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"RU001","city":"Moscow","zip":"119992","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"RU002","city":"Moscow","zip":"119992","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"RU028","city":"Moscow","zip":"119992","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"RU003","city":"Moscow","zip":"127083","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"RU007","city":"Moscow","zip":"144009","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"RU027","city":"Saransk","zip":"430030","country":"Russia","geoPoint":{"lat":54.18485,"lon":45.17166}},{"facility":"RU024","city":"Saratov","zip":"410038","country":"Russia","geoPoint":{"lat":51.54048,"lon":45.9901}},{"facility":"RU013","city":"Saratov","zip":"410060","country":"Russia","geoPoint":{"lat":51.54048,"lon":45.9901}},{"facility":"RU021","city":"Tomsk","zip":"634014","country":"Russia","geoPoint":{"lat":56.50049,"lon":84.98216}},{"facility":"RU016","city":"Tver'","zip":"170005","country":"Russia","geoPoint":{"lat":56.85836,"lon":35.90057}},{"facility":"RU014","city":"Volgograd","country":"Russia","geoPoint":{"lat":48.71378,"lon":44.4976}},{"facility":"RU011","city":"Yaroslavl","zip":"150003","country":"Russia","geoPoint":{"lat":57.62987,"lon":39.87368}},{"facility":"RU018","city":"Yekaterinburg","zip":"620905","country":"Russia","geoPoint":{"lat":56.85733,"lon":60.61529}}]},"referencesModule":{"references":[{"pmid":"22008735","type":"RESULT","citation":"Kasper S, Ebert B, Larsen K, Tonnoir B. Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder. Int J Neuropsychopharmacol. 2012 Jul;15(6):715-25. doi: 10.1017/S146114571100112X. Epub 2011 Oct 19."}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"The patients were recruited from specialist inpatient and outpatient clinics.","groups":[{"id":"FG000","title":"Placebo (Orally, Once Daily)"},{"id":"FG001","title":"Escitalopram 20 mg and Placebo (Orally, Once Daily)"},{"id":"FG002","title":"Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily)"},{"id":"FG003","title":"Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily)"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"71"},{"groupId":"FG001","numSubjects":"140"},{"groupId":"FG002","numSubjects":"139"},{"groupId":"FG003","numSubjects":"140"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"128"},{"groupId":"FG002","numSubjects":"121"},{"groupId":"FG003","numSubjects":"126"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"18"},{"groupId":"FG003","numSubjects":"14"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"6"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal of Consent","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"5"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Other Reason","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo (Orally, Once Daily)"},{"id":"BG001","title":"Escitalopram 20 mg and Placebo (Orally, Once Daily)"},{"id":"BG002","title":"Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily)"},{"id":"BG003","title":"Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily)"},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"140"},{"groupId":"BG002","value":"139"},{"groupId":"BG003","value":"140"},{"groupId":"BG004","value":"490"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42.6","spread":"11.6"},{"groupId":"BG001","value":"41.6","spread":"12.6"},{"groupId":"BG002","value":"42.6","spread":"11.8"},{"groupId":"BG003","value":"41.5","spread":"10.5"},{"groupId":"BG004","value":"42.0","spread":"11.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"96"},{"groupId":"BG002","value":"96"},{"groupId":"BG003","value":"93"},{"groupId":"BG004","value":"338"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"47"},{"groupId":"BG004","value":"152"}]}]}]},{"title":"Montgomery and Åsberg Depression Rating Scale (MADRS)","description":"The MADRS is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at 2-point intervals. The total score of the 10 items ranges from 0 to 60.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34.7","spread":"4.2"},{"groupId":"BG001","value":"35.4","spread":"4.3"},{"groupId":"BG002","value":"35.3","spread":"3.4"},{"groupId":"BG003","value":"34.7","spread":"3.8"},{"groupId":"BG004","value":"35.1","spread":"3.9"}]}]}]},{"title":"Hospital Anxiety and Depression Scale (HADS)","description":"The HADS is a patient-rated scale designed to screen for anxiety and depressive states in medical patients. It consists of two sub-scales: the D-scale measures depression and the A-scale measures anxiety. Each sub-scale contains 7 items, and each item is rated from 0 (absent) to 3 (maximum severity). The score of each sub-scale ranges from 0 to 21, and are analysed separately. The total HADS score ranges from 0 to 42.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27.5","spread":"5.9"},{"groupId":"BG001","value":"28.2","spread":"5.3"},{"groupId":"BG002","value":"28.1","spread":"5.5"},{"groupId":"BG003","value":"27.4","spread":"5.5"},{"groupId":"BG004","value":"27.8","spread":"5.5"}]}]}]},{"title":"Insomnia Severity Index (ISI)","description":"The ISI is both a brief screening measure of insomnia and an outcomes measure for use in treatment research. It is a brief self-report instrument measuring the patient's perception of his or her insomnia, and it comprises 7 items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28. 0 = no symptoms and 28 = severe symptoms.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18.4","spread":"5.0"},{"groupId":"BG001","value":"18.6","spread":"4.7"},{"groupId":"BG002","value":"18.2","spread":"4.4"},{"groupId":"BG003","value":"18.1","spread":"4.8"},{"groupId":"BG004","value":"18.3","spread":"4.7"}]}]}]},{"title":"Sheehan Disability Scale (SDS): Family Subscale","description":"The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7.0","spread":"1.4"},{"groupId":"BG001","value":"7.1","spread":"1.6"},{"groupId":"BG002","value":"7.2","spread":"1.3"},{"groupId":"BG003","value":"6.9","spread":"1.4"},{"groupId":"BG004","value":"7.1","spread":"1.4"}]}]}]},{"title":"SDS: Work Subscale","description":"The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7.3","spread":"1.2"},{"groupId":"BG001","value":"7.4","spread":"1.3"},{"groupId":"BG002","value":"7.3","spread":"1.5"},{"groupId":"BG003","value":"7.0","spread":"1.4"},{"groupId":"BG004","value":"7.2","spread":"1.4"}]}]}]},{"title":"SDS: Social Subscale","description":"The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7.0","spread":"1.4"},{"groupId":"BG001","value":"7.1","spread":"1.4"},{"groupId":"BG002","value":"7.1","spread":"1.5"},{"groupId":"BG003","value":"6.9","spread":"1.6"},{"groupId":"BG004","value":"7.0","spread":"1.5"}]}]}]},{"title":"Clinical Global Impression - Severity of Illness (CGI-S)","description":"The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.4","spread":"0.9"},{"groupId":"BG001","value":"4.5","spread":"0.9"},{"groupId":"BG002","value":"4.3","spread":"0.9"},{"groupId":"BG003","value":"4.4","spread":"0.9"},{"groupId":"BG004","value":"4.4","spread":"0.9"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Montgomery and Åsberg Depression Rating Scale (MADRS)","description":"The MADRS is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at 2-point intervals. The total score of the 10 items ranges from 0 to 60.","populationDescription":"Mean change from baseline to Week 8: Full-analysis Set (FAS), Last Observation Carried Forward (LOCF), Analysis of Covariance (ANCOVA)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline to 8 weeks","groups":[{"id":"OG000","title":"Placebo (Orally, Once Daily)"},{"id":"OG001","title":"Escitalopram 20 mg and Placebo (Orally, Once Daily)"},{"id":"OG002","title":"Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily)"},{"id":"OG003","title":"Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.4","spread":"1.1"},{"groupId":"OG001","value":"-19.0","spread":"0.9"},{"groupId":"OG002","value":"-18.5","spread":"0.9"},{"groupId":"OG003","value":"-19.4","spread":"0.9"}]}]}],"analyses":[{"groupIds":["OG001","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6405","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.45","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.34","ciUpperLimit":"1.44","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.96"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6227","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"0.47","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.41","ciUpperLimit":"2.35","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.96"}]},{"type":"SECONDARY","title":"MADRS","description":"The MADRS is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at 2-point intervals. The total score of the 10 items ranges from 0 to 60.","populationDescription":"Mean change from baseline to Week 8 (FAS, LOCF, ANCOVA)","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Scores on a scale","timeFrame":"From baseline to Week 8","groups":[{"id":"OG000","title":"Placebo (Orally, Once Daily)"},{"id":"OG001","title":"Escitalopram 20 mg and Placebo (Orally, Once Daily)"},{"id":"OG002","title":"Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily)"},{"id":"OG003","title":"Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.4","spread":"1.1"},{"groupId":"OG001","value":"-19.0","spread":"0.9"},{"groupId":"OG002","value":"-18.5","spread":"0.9"},{"groupId":"OG003","value":"-19.4","spread":"0.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-5.55","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.98","ciUpperLimit":"-3.11","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.24"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-5.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.53","ciUpperLimit":"-2.66","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.24"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-6.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.43","ciUpperLimit":"-3.56","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.24"}]},{"type":"SECONDARY","title":"Hospital Anxiety and Depression Scale (HADS)","description":"The HADS is a patient-rated scale designed to screen for anxiety and depressive states in medical patients. It consists of two sub-scales: the D-scale measures depression and the A-scale measures anxiety. Each sub-scale contains 7 items, and each item is rated from 0 (absent) to 3 (maximum severity). The score of each sub-scale ranges from 0 to 21, and are analysed separately. The total HADS score ranges from 0 to 42.","populationDescription":"Mean change from baseline to Week 8 (FAS, LOCF, ANCOVA)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Scores on a scale","timeFrame":"Mean change from baseline to Week 8","groups":[{"id":"OG000","title":"Placebo (Orally, Once Daily)"},{"id":"OG001","title":"Escitalopram 20 mg and Placebo (Orally, Once Daily)"},{"id":"OG002","title":"Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily)"},{"id":"OG003","title":"Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.7","spread":"1.0"},{"groupId":"OG001","value":"-14.7","spread":"0.8"},{"groupId":"OG002","value":"-14.1","spread":"0.8"},{"groupId":"OG003","value":"-15.0","spread":"0.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-4.98","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.13","ciUpperLimit":"-2.84","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.09"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-4.46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.60","ciUpperLimit":"-2.32","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.09"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-5.27","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.41","ciUpperLimit":"-3.13","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.09"}]},{"type":"SECONDARY","title":"Insomnia Severity Index (ISI)","description":"The ISI is both a brief screening measure of insomnia and an outcomes measure for use in treatment research. It is a brief self-report instrument measuring the patient's perception of his or her insomnia, and it comprises 7 items. Each item is rated on a 0-4 scale and the total score ranges from 0 to 28. 0 = no symptoms and 28 = severe symptoms.","populationDescription":"Mean change from baseline to Week 8 (FAS, LOCF, ANCOVA)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Scores on a scale","timeFrame":"Mean change from baseline to Week 8","groups":[{"id":"OG000","title":"Placebo (Orally, Once Daily)"},{"id":"OG001","title":"Escitalopram 20 mg and Placebo (Orally, Once Daily)"},{"id":"OG002","title":"Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily)"},{"id":"OG003","title":"Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.9","spread":"0.7"},{"groupId":"OG001","value":"-10.0","spread":"0.5"},{"groupId":"OG002","value":"-9.6","spread":"0.5"},{"groupId":"OG003","value":"-10.6","spread":"0.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-3.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.59","ciUpperLimit":"-1.58","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.77"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0006","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-2.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.15","ciUpperLimit":"-1.14","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.77"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-3.61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.13","ciUpperLimit":"-2.10","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.77"}]},{"type":"SECONDARY","title":"Sheehan Disability Scale (SDS): Family Subscale","description":"The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment.","populationDescription":"Mean change from baseline to Week 8 (FAS, LOCF, ANCOVA)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Scores on a scale","timeFrame":"Mean change from baseline to Week 8","groups":[{"id":"OG000","title":"Placebo (Orally, Once Daily)"},{"id":"OG001","title":"Escitalopram 20 mg and Placebo (Orally, Once Daily)"},{"id":"OG002","title":"Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily)"},{"id":"OG003","title":"Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"0.02"},{"groupId":"OG001","value":"-4.0","spread":"0.02"},{"groupId":"OG002","value":"-3.9","spread":"0.02"},{"groupId":"OG003","value":"-4.1","spread":"0.02"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-1.25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.85","ciUpperLimit":"-0.64","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.31"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0004","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-1.11","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.72","ciUpperLimit":"-0.50","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.31"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-1.26","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.87","ciUpperLimit":"-0.65","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.31"}]},{"type":"SECONDARY","title":"SDS: Work Subscale","description":"The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment.","populationDescription":"Mean change from baseline to Week 8 (FAS, LOCF, ANCOVA)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Scores on a scale","timeFrame":"Mean change from baseline to Week 8","groups":[{"id":"OG000","title":"Placebo (Orally, Once Daily)"},{"id":"OG001","title":"Escitalopram 20 mg and Placebo (Orally, Once Daily)"},{"id":"OG002","title":"Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily)"},{"id":"OG003","title":"Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"0.03"},{"groupId":"OG001","value":"-3.8","spread":"0.02"},{"groupId":"OG002","value":"-3.8","spread":"0.02"},{"groupId":"OG003","value":"-4.0","spread":"0.02"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0007","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-1.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.72","ciUpperLimit":"-0.46","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.32"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0013","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-1.05","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.69","ciUpperLimit":"-0.41","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.33"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-1.29","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.92","ciUpperLimit":"-0.66","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.32"}]},{"type":"SECONDARY","title":"SDS: Social Subscale","description":"The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment.","populationDescription":"Mean change from baseline to Week 8 (FAS, LOCF, ANCOVA)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Scores on a scale","timeFrame":"Mean change from baseline to Week 8","groups":[{"id":"OG000","title":"Placebo (Orally, Once Daily)"},{"id":"OG001","title":"Escitalopram 20 mg and Placebo (Orally, Once Daily)"},{"id":"OG002","title":"Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily)"},{"id":"OG003","title":"Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"0.03"},{"groupId":"OG001","value":"-3.9","spread":"0.02"},{"groupId":"OG002","value":"-3.8","spread":"0.02"},{"groupId":"OG003","value":"-4.1","spread":"0.02"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-1.20","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.82","ciUpperLimit":"-0.58","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.31"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0006","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-1.10","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.72","ciUpperLimit":"-0.48","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.32"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-1.38","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.00","ciUpperLimit":"-0.76","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.32"}]},{"type":"SECONDARY","title":"Clinical Global Impression - Severity of Illness (CGI-S)","description":"The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).","populationDescription":"Mean change from baseline to Week 8 (FAS, LOCF, ANCOVA)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Scores on a scale","timeFrame":"Mean change from baseline to Week 8","groups":[{"id":"OG000","title":"Placebo (Orally, Once Daily)"},{"id":"OG001","title":"Escitalopram 20 mg and Placebo (Orally, Once Daily)"},{"id":"OG002","title":"Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily)"},{"id":"OG003","title":"Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.04","spread":"0.13"},{"groupId":"OG001","value":"-1.65","spread":"0.10"},{"groupId":"OG002","value":"-1.58","spread":"0.10"},{"groupId":"OG003","value":"-1.76","spread":"0.10"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.89","ciUpperLimit":"-0.34","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.14"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.54","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.82","ciUpperLimit":"-0.26","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.14"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.99","ciUpperLimit":"-0.44","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.14"}]},{"type":"SECONDARY","title":"Clinical Global Impression - Global Improvement (CGI-I)","description":"The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).","populationDescription":"At Week 8 (FAS, LOCF, ANCOVA)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"Scores on a scale","timeFrame":"at Week 8","groups":[{"id":"OG000","title":"Placebo (Orally, Once Daily)"},{"id":"OG001","title":"Escitalopram 20 mg and Placebo (Orally, Once Daily)"},{"id":"OG002","title":"Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily)"},{"id":"OG003","title":"Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"139"},{"groupId":"OG003","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.97","spread":"0.12"},{"groupId":"OG001","value":"2.21","spread":"0.09"},{"groupId":"OG002","value":"2.35","spread":"0.09"},{"groupId":"OG003","value":"2.26","spread":"0.09"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.02","ciUpperLimit":"-0.50","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.13"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.62","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.88","ciUpperLimit":"-0.36","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.13"},{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.97","ciUpperLimit":"-0.45","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.13"}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"8 weeks","eventGroups":[{"id":"EG000","title":"Placebo (Orally, Once Daily)","seriousNumAffected":1,"seriousNumAtRisk":71,"otherNumAffected":12,"otherNumAtRisk":71},{"id":"EG001","title":"Escitalopram 20 mg and Placebo (Orally, Once Daily)","seriousNumAffected":0,"seriousNumAtRisk":140,"otherNumAffected":22,"otherNumAtRisk":140},{"id":"EG002","title":"Escitalopram 20 mg and Gaboxadol 5 mg (Orally, Once Daily)","seriousNumAffected":0,"seriousNumAtRisk":139,"otherNumAffected":31,"otherNumAtRisk":139},{"id":"EG003","title":"Escitalopram 20 mg and Gaboxadol 10 mg (Orally, Once Daily)","seriousNumAffected":0,"seriousNumAtRisk":140,"otherNumAffected":19,"otherNumAtRisk":140}],"seriousEvents":[{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":71},{"groupId":"EG001","numAffected":0,"numAtRisk":140},{"groupId":"EG002","numAffected":0,"numAtRisk":139},{"groupId":"EG003","numAffected":0,"numAtRisk":140}]}],"otherEvents":[{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":71},{"groupId":"EG001","numAffected":7,"numAtRisk":140},{"groupId":"EG002","numAffected":5,"numAtRisk":139},{"groupId":"EG003","numAffected":3,"numAtRisk":140}]},{"term":"Psychomotor hyperactivity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":71},{"groupId":"EG001","numAffected":0,"numAtRisk":140},{"groupId":"EG002","numAffected":0,"numAtRisk":139},{"groupId":"EG003","numAffected":2,"numAtRisk":140}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":71},{"groupId":"EG001","numAffected":0,"numAtRisk":140},{"groupId":"EG002","numAffected":3,"numAtRisk":139},{"groupId":"EG003","numAffected":1,"numAtRisk":140}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":71},{"groupId":"EG001","numAffected":3,"numAtRisk":140},{"groupId":"EG002","numAffected":2,"numAtRisk":139},{"groupId":"EG003","numAffected":3,"numAtRisk":140}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":71},{"groupId":"EG001","numAffected":3,"numAtRisk":140},{"groupId":"EG002","numAffected":4,"numAtRisk":139},{"groupId":"EG003","numAffected":2,"numAtRisk":140}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":71},{"groupId":"EG001","numAffected":0,"numAtRisk":140},{"groupId":"EG002","numAffected":1,"numAtRisk":139},{"groupId":"EG003","numAffected":2,"numAtRisk":140}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":71},{"groupId":"EG001","numAffected":4,"numAtRisk":140},{"groupId":"EG002","numAffected":8,"numAtRisk":139},{"groupId":"EG003","numAffected":3,"numAtRisk":140}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":71},{"groupId":"EG001","numAffected":2,"numAtRisk":140},{"groupId":"EG002","numAffected":1,"numAtRisk":139},{"groupId":"EG003","numAffected":1,"numAtRisk":140}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":71},{"groupId":"EG001","numAffected":2,"numAtRisk":140},{"groupId":"EG002","numAffected":0,"numAtRisk":139},{"groupId":"EG003","numAffected":0,"numAtRisk":140}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":71},{"groupId":"EG001","numAffected":1,"numAtRisk":140},{"groupId":"EG002","numAffected":6,"numAtRisk":139},{"groupId":"EG003","numAffected":2,"numAtRisk":140}]},{"term":"Dermatitis allergic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":71},{"groupId":"EG001","numAffected":0,"numAtRisk":140},{"groupId":"EG002","numAffected":0,"numAtRisk":139},{"groupId":"EG003","numAffected":0,"numAtRisk":140}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":71},{"groupId":"EG001","numAffected":1,"numAtRisk":140},{"groupId":"EG002","numAffected":1,"numAtRisk":139},{"groupId":"EG003","numAffected":2,"numAtRisk":140}]},{"term":"Rhinitis allergic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":71},{"groupId":"EG001","numAffected":0,"numAtRisk":140},{"groupId":"EG002","numAffected":0,"numAtRisk":139},{"groupId":"EG003","numAffected":0,"numAtRisk":140}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The main publication has to be published before any sub-publications."},"pointOfContact":{"title":"H. Lundbeck A/S","organization":"H. Lundbeck A/S","email":"LundbeckClinicalTrials@lundbeck.com","phone":"+45 3630 1311"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003865","term":"Depressive Disorder, Major"}],"ancestors":[{"id":"D003866","term":"Depressive Disorder"},{"id":"D019964","term":"Mood Disorders"},{"id":"D001523","term":"Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000089983","term":"Escitalopram"},{"id":"C015542","term":"gaboxadol"}],"ancestors":[{"id":"D011437","term":"Propylamines"},{"id":"D000588","term":"Amines"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D009570","term":"Nitriles"},{"id":"D001572","term":"Benzofurans"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}